Larimar Therapeutics
LRMR
71 hedge funds and large institutions have $31.5M invested in Larimar Therapeutics in 2019 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 19 increasing their positions, 26 reducing their positions, and 24 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.49% less ownership
Funds ownership: 6.4% → 5.9% (-0.49%)
16% less funds holding
Funds holding: 85 → 71 (-14)
27% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 26
46% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 24
60% less capital invested
Capital invested by funds: $78.5M → $31.5M (-$47M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $13K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.55M |
| 2 |
Millennium Management
New York
|
+$1.3M |
| 3 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$1.26M |
| 4 |
Goldman Sachs
New York
|
+$1.07M |
| 5 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$589K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.11M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$2M |
| 3 |
AG
Artal Group
Luxembourg
|
-$1.92M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.49M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$1.48M |
LRMR Hedge Fund Activity: Q2 2019 in Review
71 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q2 2019, worth a combined $31.5M — down 60% from $78.5M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of LRMR and 13 opened new positions — a net loss of 11 holders — while 26 trimmed existing stakes and 19 added.
The largest buyer was Renaissance Technologies, adding an estimated $1.55M. The largest seller was BlackRock, cutting an estimated $3.11M.
- 71 institutional investors held Larimar Therapeutics (LRMR) as of Q2 2019, down from 85 in Q1 2019.
- Funds reported $31.5M of Larimar Therapeutics stock for Q2 2019, down 60% quarter-over-quarter.
- 13 funds opened new Larimar Therapeutics positions in Q2 2019 and 24 closed out, a net change of -11 holders.
- The largest Larimar Therapeutics buyer in Q2 2019 was Renaissance Technologies, an estimated $1.55M added.
- The largest Larimar Therapeutics seller in Q2 2019 was BlackRock, an estimated $3.11M sold.
Based on aggregated 13F filings for Q2 2019.